Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen, Verogen Partner for NGS-Based Human ID Product Development, Distribution

NEW YORK – Qiagen and Verogen said on Tuesday that they have signed a partnership to provide laboratories with tools and support for next-generation sequencing-based human identification workflows.

Under the partnership, Qiagen obtains the rights to globally distribute current and future Verogen products. In addition, the companies will collaborate to commercialize Verogen's forensically validated NGS workflows with Qiagen's sample prep automation to provide full sample-to-ID workflows for human ID labs.

"This partnership with Qiagen will make it easier for the laboratories to provide more impactful answers," Verogen CEO Brett Williams said in a statement. "By combining Verogen's industry-leading NGS-based product portfolio with Qiagen's gold-standard extraction, assay, and automation solutions, we can accelerate adoption and utilization of NGS in forensic operations."

Qiagen CEO Thierry Bernard added in a statement that the partnership "will drive the adoption of NGS in human identification as it will enable our customers to gain even better insights from their casework samples. This will ultimately strengthen justice systems all over the world."

In May, Verogen announced that it had partnered with Eurofins to implement NGS into routine forensic DNA casework.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.